305 related articles for article (PubMed ID: 37023499)
1. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract][Full Text] [Related]
3. Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
[TBL] [Abstract][Full Text] [Related]
4. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
5. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC; Powell SS; Pothuri B
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
[TBL] [Abstract][Full Text] [Related]
7. Progress in Gynecologic Cancers with Antibody Drug Conjugates.
O'Malley DM; Calo CA
Curr Oncol Rep; 2021 Jun; 23(8):89. PubMed ID: 34125311
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
[TBL] [Abstract][Full Text] [Related]
9. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
[TBL] [Abstract][Full Text] [Related]
10. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates in gynecologic malignancies.
Lee EK; Liu JF
Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
[TBL] [Abstract][Full Text] [Related]
12. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
Tymon-Rosario J; Zeybek B; Santin AD
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
[TBL] [Abstract][Full Text] [Related]
13. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
Nerone M; Grande MD; Sessa C; Colombo I
Explor Target Antitumor Ther; 2022; 3(2):149-171. PubMed ID: 36046840
[TBL] [Abstract][Full Text] [Related]
14. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates for the treatment of ovarian cancer.
Calo CA; O'Malley DM
Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
[TBL] [Abstract][Full Text] [Related]
16. Recent Therapeutic Advances in Gynecologic Oncology: A Review.
Wilson EM; Eskander RN; Binder PS
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398161
[TBL] [Abstract][Full Text] [Related]
17. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract][Full Text] [Related]
18. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
[TBL] [Abstract][Full Text] [Related]
20. The Use of Targeted Agents in the Treatment of Gynecologic Cancers.
Bruce SF; Powell MA
Curr Treat Options Oncol; 2022 Jan; 23(1):15-28. PubMed ID: 35167006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]